In the majority of Ewing's family tumors, chromosomal translocation t(11;22) leads to aberrant fusion of RNAbinding protein EWS with DNA-binding ETS transcriptional factor Fli-1. EWS-Fli-1 has altered the transcriptional activity and modulating its downstream target genes through this transcriptional activity is thought to be responsible for this tumor. We have previously shown that both EWS-Fli-1 and Fli-1 have antiapoptotic activity against several apoptotic inducers. Here, we show that the transcriptional activity of EWS-Fli-1 and Fli-1 is not essential for its antiapoptotic activity. We also demonstrate that EWS-Fli-1 and Fli-1 interact with CBP through its amino-terminal region and inhibit the CBPdependent transcriptional activity of RXR. This activity appears to be independent of DNA-binding activity of EWS-Fli-1. Introduction of the dominant-negative form of CBP into Ewing's sarcoma cells sensitizes these cells against genotoxic or retinoic-acid induced apoptosis. These results suggest that the ability of EWS-Fli-1/Fli-1 to target transcriptional cofactor(s) and modulate apoptotic pathways may be responsible for its antiapoptotic and tumorigenic activities.
Introduction
Ewing's family tumors (EFT), which include Ewing's sarcoma and primitive neuroectodermal tumor, is the second most common bone and soft tissue tumor in childhood and adolescent after osteosarcoma. Recurrent chromosomal translocation t (11;22) and t(21;22) account for over 95% of this tumor, where EWS gene on chromosome 22 is juxtaposed with Fli-1 gene on chromosome 11 or erg gene on chromosome 21, respectively. Fli-1 and erg belong to ETS family of transcriptional factors. It has been shown that EWS gene fuses to other members of the ETS transcriptional family such as ETV1, FEV, E1AF, etc. in Ewing's family of tumors, although they are relatively minor. In different tumors, EWS gene is also found to be fused to other transcriptional factors such as ATF-1 in malignant melanoma of soft parts, WT1 in desmoplastic small round-cell tumor, CHOP in myxoid liposarcoma, TEC in myxoid chondrosarcoma, and CIZ/NMP4 in acute undifferentiated leukemia Martini et al., 2002) . EWS, TLS, and TATA-box binding protein TAFII68/TAF15 share the extensive sequence similarity and belong to the TET RNAbinding protein family, which includes Drosophila's SARF/Cabeza as member. TLS is found to be fused to CHOP in myxoid liposarcoma and erg in acute myeloid leukemia. TAFII68/TAF15 is found to be fused to CIZ/ NMP4 in acute myeloid leukemia (Martini et al., 2002) . The common feature of these chimeric genes is that TET N-terminal portion, which contains a degenerated repeat of serine, tyrosine, glycine, and glutamine, is fused to the C-terminal portion of a transcriptional factor, which retains an intact DNA-binding domain.
We have shown both EWS and TLS possess RNAbinding activity (Ohno et al., 1994; Prasad et al., 1994a) . Recently, it was demonstrated that this TET family takes part in RNA processing and transcription, indicating a role for EWS and TLS in splicing. Furthermore, EWS-Fli-1 and TLS-erg have been shown to inhibit splicing in an in vitro model system (Yang et al., 2000a, b) . EWS has also been found to bind to PolII, suggesting a role in transcription (Petermann et al., 1998) . We and others have identified and analysed the functions of Fli-1 and erg Reddy et al., 1987; Prasad et al., 1992 Prasad et al., , 1994b Truong and BenDavid, 2000) . Two transcriptional activation domains have been identified, which are located in the N-and C-terminal of ets domain Siddique et al., 1993) . Previously, we and others have shown that a threshold level of EWS-Fli-1 is necessary to maintain tumorigenic properties (Ouchida et al., 1995; Kovar et al., 1996; Tanaka et al., 1997) . EWS-Fli-1 can act as a potential transcriptional activator or suppressor depending on the promoter of target genes Deneen et al., 2003) . There are, however, several evidences suggesting that an alternative pathway independent of its transcriptional function is likely to be involved in the tumorigenesis of these proteins (Jaishankar et al., 1999; Welford et al., 2001) .
Considerable attempts have been made to search for effective agents such as cytokines and antibodies against cell surface receptors to induce apoptosis of EFT cells. However, EFT cells show resistance against these agents. For example, EFT is resistant to TNF-a-induced apoptosis despite the existence of the corresponding receptor, and it seems that p21 plays a role in antiapoptosis through NF-kB activity (Javelaud et al., 2000) . When introduced into fibroblast cells, EWS-Fli-1 and Fli-1 showed antiapoptotic activity against serum deprivation or Ca-ionophore treatment of fibroblasts (Yi et al., 1997; Sarrazin et al., 2002) . Furthermore, introduction of anti-sense EWS-Fli-1 sensitizes Ewing's sarcoma cells to the apoptosis induced by the genotoxic agent (Yi et al., 1997; Soldatenkov et al., 2002) .
CBP/p300 functions as a coactivator for numerous transcriptional factors and interacts with general transcriptional factors such as TBP and TFIID, suggesting that they act as bridge/scaffold within a transcriptional machinery (Goodman and Smolik, 2000) . It becomes increasingly clear that CBP/p300 is implicated in tumorigenesis and acts as a tumor suppressor. CBP is known to be mutated in human Rubinstein-Taybi Syndrome (RTS) (Petrij et al., 1995) . These patients are heterozygous for CBP and have several developmental disorders including mental retardation, digital abnormalities, facial anormalie, and tend to develop a certain type of tumor in childhood, which is shown to be of neural crest in origin (Miller and Rubinstein, 1995) . The haploinsufficiency model of CBP in this disease is supported by experimental evidence including the animal model system. Cbp þ /À mouse, which shows a developmental defect similar to RTS, also develops hematological malignancies with high incidence (Kung et al., 2000) . CBP/p300 is also involved in chromosomal translocation in leukemia. CBP is found to fuse to MLL in chronic myeloid leukemia and myelodysplastic syndrome (Satake et al., 1997; Sobulo et al., 1997; Canaani et al., 2004) . CBP also fuses to another HAT protein MOZ in AML (Borrow et al., 1996) . MLL is also found as fusion with p300 in therapy-related AML (Gayther et al., 2000; Canaani et al., 2004) .
E1A can target both CBP and p300 and alter their HAT activity. Other tumor virus proteins such as HTLV-1 Tax and human papilloma virus E6 interact with CBP/p300 and alter their activity. There are several lines of evidence that suggest that CBP/p300 promotes apoptosis (Avantaggiati et al., 1997; Lill et al., 1997; Lee et al., 1998; Yuan et al., 1999; Sargiannidou et al., 2004) . It was shown that CBP/p300 plays a role in retinoic-acid induced apoptosis (Kawasaki et al., 1998) . Introduction of E1A sensitizes Ewing's sarcoma cell against VP-16 (etoposide) and adriamycin in vitro, and in xenograft in nude mice (Zhou et al., 2001 (Zhou et al., , 2002 . It is proposed that E1A downregulates oncogene HER2/neu through the p300 pathway. We have demonstrated that EWS-ATF-1 in MMSP interacts with CBP and inhibits the transcriptional activity of target genes (Fujimura et al., 2001) . EWS is also found to be associated with CBP/p300 (Rossow and Janknecht, 2001; Araya et al., 2003) .
Here, we have attempted to understand the structural components of EWS-Fli-1, which is important for its antiapoptotic activity. Therefore, we used deletion mutants of EWS-Fli-1 and Fli-1 to evaluate their effect on antiapoptotic activity. The deletion mutants lacking transcriptional activity showed significant antiapoptotic activity. Point mutants without DNA-binding activity also possess antiapoptotic activity similar to wild type. Furthermore, both EWS-Fli-1 and Fli-1 bind to CBP and interfere with the nuclear-receptor transcriptional activity, which requires CBP/p300 as coactivator. The dominant-negative mutant of CBP sensitizes Ewing's sarcoma cells against genotoxic or retinoic-acid-induced apoptosis. These results suggest that EWS-Fli-1 and Fli-1 might act as antiapoptotic agents through targeting the CBP/p300 pathways.
Results

EWS-Fli-1 and Fli-1 mutants that are deficient in transcriptional activation function show antiapoptotic activity
Although both Fli-1 and EWS-Fli-1 suppress apoptosis of NIH3T3 cells induced by either Calcium Ionophore treatment or by serum deprivation (Yi et al., 1997) , the mechanism whereby EWS-Fli-1 interferes with the apoptotic pathway is not understood. In order to understand the antiapoptotic function of EWS-Fli-1, we have created a series of deletion mutants of EWS-Fli-1 to locate the domain responsible for this antiapoptotic activity. These deletion mutants were transiently introduced into COS-7 cells and the viability of these transfectants was analysed after induction of apoptosis by Ca-ionophore A23187 (Figure 1) . Morphology of the EWS-Fli-1 or Fli-1 transfected cells was observed to have no feature typical of apoptosis. COS-7 cells expressing EWS-Fli-1 and Fli-1 showed 60-70% viability compared to 23% for empty vector control cells after the induction (Figure 1c) .
To assess the role of EWS portion of EWS-Fli-1 in antiapoptotic activity, we transfected a deletion mutant, which contained only the carboxyl-terminal half of Fli-1 (Fli-1/break point). This mutant ], which lacks transcriptional activation function, did not completely abrogate the viability (Figure 1a) , consistent with our previous study on the erg carboxyl-terminal domain of erg (Yi et al., 1997) . To further confirm this, another transcriptional deficient mutant (EWS-Fli-1 (1-414)) in which carboxy-terminal transcriptional activation (CTA) domain of EWS-Fli-1 is deleted was examined . This deletion mutant retained antiapoptotic activity ( Figure 1a) . Similar results were obtained with MTT assay (data not shown). The expression levels for each of the mutants of EWSFli-1 and Fli-1 were compared to the wild type ( Figure 1b) . In order to assess the role of DNA-binding activity of EWS-Fli-1 and Fli-1, we constructed a point mutant by site-directed mutagenesis in the 3 0 -ets domain (DNA-binding domain) of Fli-1 and EWS-Fli-1, where Isoleucine 347 was substituted for glutamic acid (I347E). The DNA-binding ability of this deletion mutant is totally abolished and it failed to transactivate its target gene (Jaishankar et al., 1999) . We transfected this point-mutant plasmid into COS-7 cells and observed its viability. These DNA-binding mutants showed significant antiapoptotic activity (compared to that of wild type) ( Figure 1c ). Fli-1b, which has a slightly different amino-terminal region due to alternative splicing, showed an activity similar to Fli-1 (Dhulipala et al., 1998) . These results were further confirmed by MTT viability analysis and TUNNEL assays, followed by FACS analysis (data not shown). Taken together, these results suggested that transcriptional activity is not absolutely essential for the antiapoptotic activity of EWS-Fli-1.
Both EWS-Fli-1 and Fli-1 associate with CREB-binding protein in vitro and in vivo Given that the antiapoptotic activity does not fully depend on transcriptional activity, it could be possible that EWS-Fli-1's ability to interact with the other protein partner(s) of EWS-Fli-1 or Fli-1 might govern this antiapoptotic activity. CBP/p300 is shown to have a pivotal role in apoptotic pathway. Recently, we have found CBP to interact with EWS-ATF-1 and interfere with the transcriptional activity of p53, which requires CBP/p300 as a coactivator for transcriptional activation (Fujimura et al., 2001) . These results have driven us to test whether EWS-Fli-1 or Fli-1 associates with CBP.
To analyse whether CBP can interact with either EWS-Fli-1 or Fli-1, GST pull-down assays were performed with in vitro translated EWS-Fli-1 or Fli-1. The amino-terminal region of CBP (1-452 aa) was expressed as a GST-fusion protein, and then tested for its ability to bind to in vitro translated EWS-Fli-1 or Fli-1 using GST pull-down assay ( Figure 2a ). EWS-Fli-1 was found to bind specifically to GST-CBP (1-452 aa) (Figure 2a, lane 3) , but not to GST (Figure 2a, lane 2) . Similarly, Fli-1 was found to bind specifically to GST-CBP (1-452 aa) (data not shown).
To study whether EWS-Fli-1 or Fli-1 could interact with the amino-terminal region of CBP in mammalian cells, we performed a co-immunoprecipitation assay followed by Western blot analysis in COS-7 cells. We cotransfected COS-7 cells with HA-epitope-tagged aminoterminal-CBP (1-452 aa) and FLAG-epitope-tagged full-length Fli-1. At 48 h after transfection, cell lysates were prepared and subjected to immunoprecipitation with anti-FLAG antibody. The immunoprecipitated complex was subjected to Western blotting with anti-HA antibody. As shown in Figure 2b , the aminoterminal region of CBP was co-precipitated with the full-length Fli-1 in Fli-1-transfected cells (Figure 2b To further confirm the in vivo interaction of EWSFli-1 and CBP, we investigated whether endogenous EWS-Fli-1 interacts with endogenous CBP in Ewing's sarcoma cells . Cell lysates from TC-135 cells were immunoprecipitated with anti-CBP antibody and the immunocomplexes were subjected to Western blotting using Fli-1 antibody. As shown in Figure 2c (left panel,  lane 3) , EWS-Fli-1 was co-immunoprecipitated along with CBP, but not with a control IgG antibody. This interaction was confirmed by reciprocal co-immunoprecipitation (with anti-Fli-1 antibody). Anti-Fli-1 antibody is able to co-immunoprecipitate CBP (Figure 2c right panel, lane 2). These results strongly suggest that EWS-Fli-1 associates with CBP in Ewing's sarcoma cells.
Aberrant EWS-Fli-1 inhibits the transcriptional activity of retinoic acid receptor
There are several lines of evidence which suggest that squelching of the limiting amount of CBP/p300 causes mutual transcriptional repression among the various classes of transcriptional factors. For example, nuclear hormone receptors require CBP/p300 as coactivator for their transcriptional activity. This activity was abrogated by the introduction of other transcriptional factors such as AP-1 (Kamei et al., 1996) . Darby et al. demonstrated that the mutual interference between Fli-1 and retinoic-acid receptors is independent of their DNA-binding activity. Since both retinoic-acid receptors and EWS-Fli-1/Fli-1 bind to the amino-terminal region of CBP, we hypothesized that the EWS-Fli-1 or Fli-1 might affect the activity of nuclear receptors by interfering with their association with CBP/p300.
To test this hypothesis, we examined the effect of EWS-Fli-1 or Fli-1 on RXRa-mediated transcriptional activation function. We have transfected Fli-1 or EWSFli-1 expression plasmid along with RXRa expression plasmid, RXRa reporter plasmid (DR1(G)-tk-CAT), and a reference plasmid (CMV b-gal) into COS-7 cells. RXRa-mediated transcriptional activity was measured using CAT assay. Our results demonstrate that RXRa strongly induces reporter plasmid transcriptional activity upon addition of retinoid (9-cis-retinoic acid) (Figure 3a) . Expression of Fli-1 or EWS-Fli-1 inhibited RXRa-mediated transcriptional activity (Figure 3a , top and bottom panels), suggesting that EWS-Fli-1 and Fli-1 function as repressors of RXRa transcription. To test whether the transcriptional activation function of EWSFli-1 or Fli-1 has any role in this inhibition, we cotransfected DNA-binding point mutants of Fli-1 and EWS-Fli-1 along with RXRa expression plasmid as described above. Both EWS-Fli-1 and Fli-1 DNAbinding point mutants inhibit RXR-mediated transactivation to the same extent compared to wild type, suggesting that the DNA-binding activity of EWS-Fli-1 and Fli-1 may not have a significant role in this inhibition (data not shown).
CBP/p300 is known to play an important role in the retinoic-acid-induced apoptosis (Kawasaki et al., 1998) . -3) , and then subjected to GST pull-down assay as described (Wang et al., 1997) . Lane 1, in vitro translation of EWS-Fli-1; lanes 2 and 3 represent [ Figure 4b ). After 48 h of transfection, these cells were treated with 9-cis-retinoic acid for 48 h and the cell viability was measured ( Figure 3b ). As expected, empty vector (pCruz-HA)-transfected Ewing's sarcoma cells showed resistance to cell death induced by 9-cis-retinoic acid ( Figure 3b, lane 2) . However, Ewing's sarcoma cells transfected with N-CBP (pCruz-HA-CBP) showed susceptibility to cell death induced by 9-cis-retinoic acid (Figure 3b, lane 3) . We have monitored the expression levels of EWS-Fli-1 and N-CBP in these transfected cells (Figure 3c ). The expression of N-CBP does not have any effect on the level of expression of EWS-Fli-1 (Figure 3c ). These results suggest that EWS-Fli-1 and Fli-1 interfere with RXR/CBP-mediated transactivation and apoptosis by interfering/sequestration of CBP.
Amino-terminal portion of CBP impairs the antiapoptotic activity of EWS-Fli-1
Since CBP plays a critical role in apoptosis, we tested whether a dominant-interfering/-negative mutant of CBP (N-CBP) inhibits the antiapoptotic function of EWS-Fli-1 when the cells were exposed to Calcium Ionophore or etoposide. Transfection of the carboxyl-terminal deletion mutant N-CBP (1-452 aa) alone showed no effect on the viability of COS-7 cells induced with Calcium Ionophore (A23187) (Figure 4a, lane 2) . As expected, EWSFli-1/Fli-1-alone-transfected cells showed significant antiapoptotic activity (Figure 4a, lanes 3 and 5) . However, when N-CBP was transfected along with either EWS-Fli-1 or Fli-1 (Figure 4a, lanes 4 and 6) , it profoundly impaired the viability of transfected cells induced with Calcium Ionophore to the control level, suggesting that N-CBP counteracts the antiapoptotic activity of EWS-Fli-1 and Fli-1. We have monitored the expression levels of EWS-Fli-1, Fli-1, and N-CBP in these transfected cells, as shown in Figure 4b .
To investigate the possibility whether N-CBP abrogates the antiapoptotic activity of EWS-Fli-1 in Ewing's sarcoma cells treated with etoposide, we transfected the plasmid expressing N-CBP into Ewing's sarcoma cells (TC-135) (Figure 4c ). Western blot analysis showed that N-CBP did not modulate the expression level of endogenous EWS-Fli-1 (Figure 4d, lane 2) . Parental TC135 cells demonstrated very little apoptosis when induced with etoposide (VP16) (Figure 4c , lane 1). When transfected with N-CBP, the level of viability of cells was reduced almost half compared to the vector control ( Figure 4c, lane 2) . This reduction is comparable to the Ewing's sarcoma cells transfected with anti-sense EWS-Fli-1 (data not shown). These results show that N-CBP inhibits the antiapoptotic activity of EWS-Fli-1 in a dominant-negative manner, suggesting the importance of EWS-Fli-1/CBP interactions in the regulation of apoptosis induced by Calcium Ionophore or etoposide.
Discussion
Our results demonstrate that both deletion and DNAbinding point mutants (which has lost transcriptional activity on target promoters) retain antiapoptotic activity against several apoptotic inducers, suggesting that the transcriptional activity of EWS-Fli-1 and Fli-1 is not essential for its antiapoptotic activity. There are several lines of evidence that suggest that the DNAbinding activity of EWS-Fli-1 is independent of transforming activity. Several ETS domain point mutants that disrupt DNA-binding ability and transcriptional activity on the target promoter still maintain transforming potency in anchorage-independent growth and tumorigenicity in SCID mouse (Jaishankar et al., 1999; Welford et al., 2001) . However, the fact that all fusion products of EFT preserve an intact ETS domain implies the importance of this domain in functions other than DNA-binding activity. In fact, loss of ETS domain resulted in a loss of transforming potential (May et al., 1993) . Our results showed that the carboxyl-terminal half-deletion mutant, which has lost the EWS half but contains the ETS domain, still has antiapoptotic activity (though weak), suggesting the importance of ETS domain in the antiapoptotic function. These results suggest that ETS domain might have an alternative role in protein-protein or protein-RNA interaction, which may also play a role in the tumorigenesis (Jaishankar et al., 1999) .
Our results show that EWS-Fli-1 and Fli-1 associate with CBP in vitro and in vivo. Interaction between normal EWS and CBP has been described previously (Rossow and Janknecht, 2001; Araya et al., 2003) . Several lines of evidence suggest that CBP/p300 acts as a tumor suppressor and plays a role in apoptosis. In chromosomal translocations associated with tumor development, it was shown that the aberrant fusion product MLL-AFX (involved in chromosomal translocation t(X;11) in a subset of acute leukemias), which lacks intact forkhead DNA-binding domain, can interact with CBP and suppress forkhead protein-mediated apoptosis (So and Cleary, 2002) . Tumor virus proteins are known to target CBP/p300 and modulate their transcriptional coactivator function. Adenovirus E1A can bind to both CBP and p300, inhibit the transcriptional activity of transcriptional factors mediated by CBP/p300, and modify the pattern of gene expression. E1A also inhibits the apoptotic pathway by binding with CBP/p300. Recently, it has been shown that not only viral protein but also a growing number of cellular transcriptional factors squelch CBP/p300 and inhibit their HAT activity. These include PU.1 (Hong et al., 2002) , Twist (Hamamori et al., 1999) , HOX transcriptional factors (Shen et al., 2001) , and EBF (Zhao et al., 2003) .
Our results indicate that EWS-Fli-1 and Fli-1 inhibit the transcriptional activity of RXR upon binding with ligand. We also showed that the dominant-negative form of CBP (N-CBP) sensitizes Ewing's sarcoma cells to both genotoxic agent-and retinoic acid-mediated apoptosis. It was shown that CBP/p300 is involved in retinoic acid-induced apoptosis in mouse embryonal carcinoma F9 cells using a ribozyme designed to specifically target CBP or p300 (Kawasaki et al., 1998) . Fli-1 and retinoic acid receptors mutually interfere in their transcriptional activity although there is no indication for direct binding of Fli-1 to retinoic acid receptors. These results suggested that the sequestering of common factor(s) by Fli-1 may be responsible for the mutual interference of Fli-1 and retinoic acid receptors (Darby et al., 1997) . This relationship of mutual interference is also found in PU.1 (Gauthier et al., 1993) . In the cross coupling between AP-1 and nuclear receptors, competition for limiting amounts of CBP may account for this interference (Kamei et al., 1996) . The normal EWS also inhibits the transcriptional activity of nuclear receptors such as RAR and HNF4, and this inhibition was relieved by an increased level of CBP (Araya et al., 2003) . Our results suggest that overexpressed Fli-1 may target CBP/p300 and this may be responsible for erythroleukemias induced by Friend virus. These observations are consistent with our hypothesis that targeting CBP/p300 by EWS-Fli-1 may account for the inhibition of retinoic acid-induced apoptosis in Ewing's sarcoma. Therefore, the protein-protein interactions of aberrant onco-fusion protein EWS-Fli-1 and global cofactor CBP/p300 may provide new clues to developing therapeutic strategies to cure Ewing's sarcoma and other related cancers.
Materials and methods
Cell lines
Both monkey kidney COS-7 cells and human breast carcinoma MCF-7 cells were maintained in DMEM supplemented with 10% fetal bovine serum, 50 U/ml penicillin, and 50 mg/ml streptomycin. Ewing's sarcoma TC-135 cells were grown in RPMI-1640 supplemented with 10% fetal bovine serum, 50 U/ ml penicillin, and 50 mg/ml streptomycin. Cells were maintained at 371C in a 5% CO 2 atmosphere.
Plasmids and transfection
Cloning of Fli-1, EWS-Fli-1, and their deletion mutants was described previously (Ohno et al., 1994) . To substitute isoleucine 347 with glutamic acid (I347E) of Fli-1/EWS-Fli-1, we performed PCR using Fli-1 cDNA as a template, and the following oligonucleotides to mutate isoleucine (underlined) to glutamic acid: GTTATTACTATGATAAAA ACGAGATGACCAAAGTGCACGGC (sense) and GCCGT GCACTTTGGTCATCTCGTTTTTATCATAGTAAT (antisense).
PCR products were cloned into pSG5, and then subcloned into pEGFP (BD Bioscience), and pCruz OctA (Santa Cruz Biotechnology, Inc) vector, respectively. Entire sequences of inserts were verified after cloning. The amino-terminal region of mouse CBP (N-CBP; 1-452 aa) was generated with PCR and cloned into a pCruz HA vector (Santa Cruz Biotechnology, Inc). Transfection was carried out using FuGENE 6 transfection reagent (Roche Applied Bioscience) according to the manufacturer's instruction, with slight modification. Briefly, 50 000 cells were seeded onto six-well plates. After 24 h, the cells were replenished with an appropriate medium containing 5% fetal bovine serum and incubated for further 3 h before transfection. In all, 1 mg of DNA was transfected with 3 ml of FuGENE 6 reagent and incubated for further 24 h. Cells were replenished with fresh medium before the induction of apoptosis. Stable clones were selected in the medium containing 600 mg/ml G418 for 2 weeks. CAT assay was performed as previously described (Fujimura et al., 2001) .
In vivo and in vitro interaction assay
Western blot assay was performed using either Fli-1(C-19) or ets-1/ets-2 (C-275) rabbit polyclonal antibodies to detect both Fli-1 and EWS-Fli-1. The expression of endogenous CBP was detected by a rabbit polyclonal antibody. Transfected cells were harvested by scraping with lysis buffer containing 1% Igepal CA-630 (SIGMA), 0.5% sodium deoxycholate, 0.1% SDS, Complete protease inhibitor cocktail (Roche Applied Bioscience), and 0.1 mM PMSF in PBS, sonicated briefly, and centrifuged to obtain the supernatant. Electrophoresis was performed using 10% SDS-polyacrylamide gels, and proteins were transferred to nitrocellulose membranes (Amersham International).
Immunoprecipitation was performed by incubating the cell lysates with the corresponding antibodies at 41C overnight. The immune complex was bound to protein A/G agarose beads (Santa Cruz) for 1 h at 41C. After washing, the bound proteins were eluted by boiling in SDS-sample buffer.
Anti-HA Rat monoclonal antibody (clone 3F10) conjugated with peroxidase (Roche Applied Science) was used to detect the expression of transfected N-CBP. GST pull-down assay was performed as described previously.
Apoptosis analysis and cell viability assay
To detect DNA fragmentation as a measure of apoptosis, MCF-7 stable cell lines were treated with either Calcium Ionophore (A23187) or all-trans-retinoic acid (tRA) for 24 h. DNA fragmentation in cells was detected by terminal deoxynucleotidyl transferase UTP nick end labeling (TUNEL) reaction using an in situ cell detection kit (Roche Applied Bioscience) followed by FACS analysis.
In some cases, cell viability was assessed by counting green fluorescent positive cells after induction of the appropriate agent. Enhanced green fluorescent protein was expressed by co-transfection with either the appropriate gene or fusion product to the gene of interest. Transfected cells were cultured for 48 h prior to the administration of agent and then incubated further 24 h before counting. Enhanced green fluorescent positive cells were scored under fluorescent microscopy (Olympus). In certain cases, cell viability was assayed using MTT metabolic assay as described previously (Yi et al., 1997) .
